Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oji

Showing results (471-480 of 589) with videos related to

Pageof 59
Sort By:
Langenbeck'S Archives of Surgery|August 7, 2024
Comparison of laparoscopic liver resection for the ventral versus the dorsal areas of segment 8Kentaro Oji, Takeshi Urade, Masahiro Kido, et al.
Neurology|January 5, 2018
Serum caffeine and metabolites are reliable biomarkers of early Parkinson diseaseMotoki Fujimaki, Shinji Saiki, Yuanzhe Li, et al.
Anticancer Research|March 10, 2015
Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cellsAkiko Katsuhara, Fumihiro Fujiki, Nao Aoyama, et al.
Cancer Immunology, Immunotherapy : CII|March 17, 2015
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological responseNaoya Hashimoto, Akihiro Tsuboi, Naoki Kagawa, et al.
Annals of Clinical and Translational Neurology|February 15, 2020
Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 diseaseShin-Ichi Ueno, Taku Hatano, Ayami Okuzumi, et al.
Neuro-Oncology Advances|August 6, 2021
Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapiesChisato Yokota, Jun Nakata, Koji Takano, et al.
International Journal of Hematology|August 5, 2003
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosisYoshihiro Oka, Akihiro Tsuboi, Masaki Murakami, et al.
Microbiology and Immunology|June 21, 2007
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinomaTatsuo Iiyama, Keiko Udaka, Sachihiko Takeda, et al.
Bone Marrow Transplantation|June 11, 2003
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousinK Ikegame, C Mukouchi, A Kunitomi, et al.
Nature Genetics|June 5, 2007
Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasiaKarl-Heinz Grzeschik, Dorothea Bornholdt, Frank Oeffner, et al.
Pageof 59

Showing results (471-480 of 589) with videos related to

Sort By:
Pageof 59
Langenbeck'S Archives of Surgery|August 7, 2024
Comparison of laparoscopic liver resection for the ventral versus the dorsal areas of segment 8Kentaro Oji, Takeshi Urade, Masahiro Kido, et al.
Neurology|January 5, 2018
Serum caffeine and metabolites are reliable biomarkers of early Parkinson diseaseMotoki Fujimaki, Shinji Saiki, Yuanzhe Li, et al.
Anticancer Research|March 10, 2015
Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cellsAkiko Katsuhara, Fumihiro Fujiki, Nao Aoyama, et al.
Cancer Immunology, Immunotherapy : CII|March 17, 2015
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological responseNaoya Hashimoto, Akihiro Tsuboi, Naoki Kagawa, et al.
Annals of Clinical and Translational Neurology|February 15, 2020
Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 diseaseShin-Ichi Ueno, Taku Hatano, Ayami Okuzumi, et al.
Neuro-Oncology Advances|August 6, 2021
Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapiesChisato Yokota, Jun Nakata, Koji Takano, et al.
International Journal of Hematology|August 5, 2003
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosisYoshihiro Oka, Akihiro Tsuboi, Masaki Murakami, et al.
Microbiology and Immunology|June 21, 2007
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinomaTatsuo Iiyama, Keiko Udaka, Sachihiko Takeda, et al.
Bone Marrow Transplantation|June 11, 2003
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousinK Ikegame, C Mukouchi, A Kunitomi, et al.
Nature Genetics|June 5, 2007
Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasiaKarl-Heinz Grzeschik, Dorothea Bornholdt, Frank Oeffner, et al.
Pageof 59